接受透析的肾衰竭成人中二价mRNA COVID-19疫苗的有效性:来自美国医疗保险和医疗补助服务中心的队列研究
该回顾性队列研究利用美国医疗保险按服务付费索赔数据,评估了2022年9月4日至2023年4月1日期间接受维持性透析的肾衰竭成人中二价mRNA COVID-19疫苗相对于仅接种原始单价疫苗的有效性。结果显示,二价疫苗对就医性COVID-19的相对有效性为41%(95% CI,37%-46%),对COVID-19相关住院、危重疾病和死亡的有效性分别为49%、53%和54%,但有效性随时间减弱。
要点
- 二价mRNA疫苗对透析患者就医性COVID-19的相对有效性为41%(95% CI,37%-46%)。
- 对COVID-19相关住院、危重疾病和死亡的有效性分别为49%、53%和54%。
- 接种后7-59天有效性为50%,60-206天降至33%,提示有效性随时间减弱。
核心结论
- 研究结果表明,二价mRNA COVID-19疫苗剂量为既往接种过疫苗的维持性透析肾衰竭患者提供了针对COVID-19疾病的保护,但估计的有效性随时间减弱。
研究设计与样本
- 回顾性队列研究,使用美国医疗保险按服务付费索赔数据,纳入2022年9月4日至2023年4月1日期间接受维持性透析的年龄≥18岁肾衰竭受益人。
- 暴露为接种二价mRNA COVID-19疫苗,对照为仅接种原始单价COVID-19疫苗剂量。
- 采用加权Cox回归模型估计调整后风险比,相对疫苗有效性计算为1减去调整后风险比。
主要发现
- 在无其他免疫抑制状况的维持性透析肾衰竭成人中,二价mRNA COVID-19疫苗剂量相对于仅接种原始单价疫苗剂量,对就医性COVID-19的相对估计有效性为41%(95% CI,37%-46%)。
- 对COVID-19相关住院的相对估计有效性为49%(95% CI,43%-54%)。
- 对危重COVID-19疾病的相对估计有效性为53%(95% CI,44%-61%)。
- 对COVID-19相关死亡的相对估计有效性为54%(95% CI,42%-63%)。
- 对就医性COVID-19的估计疫苗有效性在二价疫苗接种后7-59天为50%(95% CI,44%-55%),在接种后60-206天为33%(95% CI,26%-39%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 可能存在潜在错分偏倚。
- 可能存在残余混杂。
- 可能存在普遍性担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONAL & OBJECTIVE: Patients with kidney failure treated with maintenance dialysis have an increased risk of severe disease due to SARS-CoV-2 infection, the virus that causes COVID-19. Previous studies have shown that COVID-19 vaccination is effective against severe COVID-19 illness in the general population. However, less is known about populations at greater risk for severe disease. This investigation examined the real-world effectiveness of bivalent messenger RNA (mRNA) COVID-19 vaccination against clinical outcomes among patients treated with maintenance dialysis. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Medicare Fee-for-Service (FFS) claims data for beneficiaries aged ≥18 years with kidney failure receiving maintenance dialysis between September 4, 2022, and April 1, 2023. EXPOSURE: Bivalent mRNA COVID-19 vaccination compared with receipt of original monovalent COVID-19 doses alone. OUTCOME: Medically attended COVID-19, which was defined as the occurrence of a COVID-19-associated outpatient encounter, COVID-19-associated hospitalization, critical COVID-19 illness, or COVID-19-associated death, overall as well as each COVID-19-associated outcome individually. ANALYTICAL APPROACH: Relative vaccine effectiveness against COVID-19-associated outcomes was calculated as 1 - adjusted hazard ratio, with the adjusted hazard ratio comparing rates of outcomes by vaccination status estimated using a weighted Cox regression model. RESULTS: Compared with receipt of original monovalent COVID-19 vaccine doses, the relative estimated effectiveness of a bivalent mRNA COVID-19 vaccine dose was 41% (95% CI, 37%-46%) against medically attended COVID-19, 49% (95% CI, 43%-54%) against COVID-19-associated hospitalization, 53% (95% CI, 44%-61%) against critical COVID-19 illness, and 54% (95% CI, 42%-63%) against COVID-19-associated death among adults with kidney failure treated with maintenance dialysis without additional immunocompromising conditions. Estimated vaccine effectiveness against medically attended COVID-19 was 50% (95% CI, 44%-55%) 7-59 days after bivalent vaccination and 33% (95% CI, 26%-39%) 60-206 days after bivalent vaccination. LIMITATIONS: Potential misclassification bias, residual confounding, and generalizability concerns may exist. CONCLUSIONS: These findings suggest a bivalent mRNA COVID-19 vaccine dose provided protection against COVID-19 disease among previously vaccinated persons with kidney failure receiving maintenance dialysis, but the estimated effectiveness waned over time. PLAIN-LANGUAGE SUMMARY: People with kidney failure treated with maintenance dialysis are at increased risk of severe COVID-19. The role of COVID-19 vaccination in this population is not well characterized. Between September 4, 2022, and April 1, 2023, the relative effectiveness of a bivalent mRNA COVID-19 vaccine dose compared with receipt of original monovalent COVID-19 vaccine doses alone among adults aged ≥18 years with kidney failure treated with maintenance dialysis but without additional immunocompromising conditions was 41% (95% CI, 37%-46%) against medically attended COVID-19, with the estimated effectiveness being similar for severe outcomes like COVID-19-associated hospitalization and COVID-19-associated death. COVD-19 vaccine effectiveness among these adults waned with more time since vaccination.
引用
- Payne AB, Novosad S, Sung HM, et al. Effectiveness of Bivalent mRNA COVID-19 Vaccine Among Adults With Kidney Failure Receiving Dialysis: A Cohort Study From the Centers for Medicare and Medicaid Services. Am J Kidney Dis. 2025. PMID: 40976332. doi:10.1053/j.ajkd.2025.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。